U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C26H28Cl2N4O4
Molecular Weight 531.431
Optical Activity ( - )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LEVOKETOCONAZOLE

SMILES

CC(=O)N1CCN(CC1)C2=CC=C(OC[C@@H]3CO[C@](CN4C=CN=C4)(O3)C5=C(Cl)C=C(Cl)C=C5)C=C2

InChI

InChIKey=XMAYWYJOQHXEEK-ZEQKJWHPSA-N
InChI=1S/C26H28Cl2N4O4/c1-19(33)31-10-12-32(13-11-31)21-3-5-22(6-4-21)34-15-23-16-35-26(36-23,17-30-9-8-29-18-30)24-7-2-20(27)14-25(24)28/h2-9,14,18,23H,10-13,15-17H2,1H3/t23-,26-/m1/s1

HIDE SMILES / InChI

Molecular Formula C26H28Cl2N4O4
Molecular Weight 531.431
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Ketoconazole is an azole antifungal. Ketoconazole was the first broad-spectrum oral antifungal agent available to treat systemic and superficial mycoses. Evidence of hepatotoxicity associated with its use emerged within the first few years of its approval. Due to its hepatotoxic side effects, oral ketoconazole was withdrawn from the European and Australian markets in 2013. The United States imposed strict relabeling requirements and restrictions for prescription, with Canada issuing a risk communication echoing these concerns. Today, oral ketoconazole is only indicated for endemic mycoses, where alternatives are not available or feasible. Meanwhile, topical ketoconazole is effective, safe, and widely prescribed for superficial mycoses, particularly as the first-line treatment for tinea versicolor. Topically administered ketoconazole is usually prescribed for fungal infections of the skin and mucous membranes, such as athlete's foot, ringworm, candidiasis (yeast infection or thrush), jock itch, and tinea versicolor. Topical ketoconazole is also used as a treatment for dandruff (seborrheic dermatitis of the scalp) and for seborrheic dermatitis on other areas of the body, perhaps acting in these conditions by suppressing levels of the fungus Malassezia furfur on the skin. Ketoconazole interacts with 14-α demethylase, a cytochrome P-450 enzyme necessary for the conversion of lanosterol to ergosterol. This results in inhibition of ergosterol synthesis and increased fungal cellular permeability. Other mechanisms may involve the inhibition of endogenous respiration, interaction with membrane phospholipids, inhibition of yeast transformation to mycelial forms, inhibition of purine uptake, and impairment of triglyceride and/or phospholipid biosynthesis. Ketoconazole can also inhibit the synthesis of thromboxane and sterols such as aldosterone, cortisol, and testosterone. Ketoconazole is active against clinical infections with Blastomyces dermatitidis, Coccidioides immitis, Histoplasma capsulatum, Paracoccidioides brasiliensis.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
2.2 µM [EC50]
17.5 µM [IC50]
116.0 nM [IC50]
48.0 nM [IC50]
1.0 µM [IC50]
27.0 nM [Kd]
0.18 µM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
NIZORAL
Curative
NIZORAL
Curative
NIZORAL
Curative
NIZORAL Tablets
Curative
NIZORAL Tablets
Primary
Unknown
Primary
Unknown

Cmax

ValueDoseCo-administeredAnalytePopulation
6 μg/mL
200 mg single, oral
KETOCONAZOLE plasma
Homo sapiens
3.5 μg/mL
200 mg single, oral
KETOCONAZOLE plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
1053 mg × min/L
200 mg single, oral
KETOCONAZOLE plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
122 min
200 mg single, oral
KETOCONAZOLE plasma
Homo sapiens
2 h
200 mg single, oral
KETOCONAZOLE plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
200 mg single, oral
KETOCONAZOLE plasma
Homo sapiens

Doses

AEs

Sourcing

PubMed

Sample Use Guides

In Vivo Use Guide
Subjects with type 2 diabetes who were between the ages of 18 and 70 years and were drug naive or receiving metformin at a stable dose were randomized to receive one of the following once daily at bedtime for 14 days: ketoconazole 400 mg; 2S,4R ketoconazole 200, 400, or 600 mg; or placebo. In a three period cross-over study in 24 healthy subjects dosed with placebo, 2S,4R ketoconazole or ketoconazole at a dose of 400mg QD.
Route of Administration: Oral
In Vitro Use Guide
30 or 50 uM 2S,4R ketoconazole induced CYP1A1 mRNA and protein in human HepG2 cells
Substance Class Chemical
Record UNII
2DJ8R0NT7K
Record Status Validated (UNII)
Record Version